Evio Pharmacy Solutions plans to provide biosimilar alternatives for autoimmune and cancer therapeutics.
Evio Pharmacy Solutions has contracted with biosimilars manufacturers for autoimmune disease and cancer therapeutics under the medical benefit. All five of Evio's investor health plans have chosen to take part in the initial offering as customers.
Evio is an independent pharmacy solutions company launched in June 2021 to improve affordability and outcomes of medications. It will look to use real-world evidence to create new clinical insights and focus on value-based care and the alignment of payment with outcomes, Hank Schlissberg, Evio’s president and CEO, said in an interview at the time.
“We have access to very unique data because it is the intersection of pharmaceutical and medical. The health plans have real-world evidence of how a drug is performing in the real-world," he said.
The five Blue Cross plans — Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan, Blue Shield of California, Highmark Inc., and Independence Blue Cross — have all invested in Evio. In total, the plans provide coverage to more than 20 million members across the United States.
Evio is creating its own analytics systems that will leverage the five plans’ claims data but will also look to partner with other analytics and solution providers. The company aims to provide greater transparency to patients and providers, and to see how a drug performs in the real world.
“The high cost of medications for individuals with chronic conditions can be a deterrent for filling and taking medications; we're hoping the introduction and acceleration of high-quality biosimilar alternatives, especially for new patients, will be an appropriate way to get lifesaving medications to high-risk patients in a more affordable way,” Pharmacist Helen Sherman, Evio’s chief transformation officer, said in a press release.